Task Force Finds Several Methods Equally Effective for Colorectal Cancer Screening

Publication
Article
OncologyONCOLOGY Vol 22 No 12
Volume 22
Issue 12

In a change from its previous recommendation, the US Preventive Services Task Force now recommends that adults aged 50 to 75 be screened for colorectal cancer using annual high-sensitivity fecal occult blood testing, sigmoidoscopy every 5 years with fecal occult testing between sigmoidoscopic exams, or colonoscopy every 10 years. According to the Task Force, good evidence exists that using these methods save lives.

In a change from its previous recommendation, the US Preventive Services Task Force now recommends that adults aged 50 to 75 be screened for colorectal cancer using annual high-sensitivity fecal occult blood testing, sigmoidoscopy every 5 years with fecal occult testing between sigmoidoscopic exams, or colonoscopy every 10 years. According to the Task Force, good evidence exists that using these methods save lives. The recommendation and the accompanying summary of evidence is posted in the Annals of Internal Medicine online at www.annals.org and appeared in the Nov 4 print edition of the journal.

The recommendations and materials for clinicians are available on the AHRQ website at http://www.ahrq.gov/clinic/uspstf/uspscolo.htm.

Recent Videos
Genetic backgrounds and ancestry may hold clues for better understanding pancreatic cancer, which may subsequently mitigate different disparities.
Factors like genetic mutations and smoking may represent red flags in pancreatic cancer detection, said Jose G. Trevino, II, MD, FACS.
Skin toxicities are common with targeted therapies for GI malignancies but can be remedied by preventative measures and a collaboration with dermatology.
212Pb-DOTAMTATE showed “unexpectedly good” outcomes among those with gastroenteropancreatic neuroendocrine tumors, said Mary Maluccio, MD, MPH, FACS.
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
Receiving information regarding tumor-associated antigens or mutational statuses from biopsies may help treatment selection in GI malignancies.
Better defining which patients with GI cancers are preferred candidates for adoptive cellular therapies may help optimize outcomes.
Related Content